Alexander Vos, VarmX CEO
'Fundamentally different' from Portola, Dutch biotech lands €32M to steer anti-anticoagulant through the clinic
Portola may not have had much success proving the commercial value of an anti-anticoagulant, but that’s not stopping European investors from pouring $36.2 million …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.